Immunovaccine Inc.

Immunovaccine Inc.

June 16, 2011 09:02 ET

Immunovaccine Nominates Brad Thompson for Appointment to the Board

HALIFAX, NOVA SCOTIA--(Marketwire - June 16, 2011) - Immunovaccine Inc. (TSX VENTURE:IMV) announced today that Brad Thompson, Ph.D., will join its Board of Directors. Dr. Thompson is the co-founder and chief executive of Oncolytics Biotech Inc. (TSX:ONC)(NASDAQ:ONCY). He will be nominated to the Board at Immunovaccine's Annual General Meeting (AGM) on June 22, 2011.

"Dr. Thompson brings us broad experience in both the biotechnology industry and the public markets," said Albert Scardino, speaking on behalf of Immunovaccine's Board. "We're gratified that he sees such promise in our science and such opportunity in our company." Pending shareholder approval, Dr. Thompson will become a director of Immunovaccine at the conclusion of the AGM.

"I'm excited to become part of Immunovaccine's future," said Dr Thompson. "Their approach to vaccine delivery offers hope in a wide range of both infectious diseases and cancer."

Immunovaccine successfully completed a detailed analysis of patients enrolled in its first Phase I clinical trial earlier this month. The trial data shows that the DPX-0907 vaccine was safe and able to stimulate a targeted immune response. The Company is now focused on the development of DPX-Survivac, a vaccine that may be effective in treating ovarian cancer and at least eight other types of malignancies.

Brad Thompson, Ph.D., is Executive Chairman, Chief Executive Officer and President of Oncolytics Biotech Inc. and is the current Chairman of BIOTECanada. Prior to joining Oncolytics, he served as Chief Executive Officer of Iteration Energy Ltd. (formerly SYNSORB Biotech Incorporated), from May 1994 to February 1999, and was Head of Biotechnology at The Alberta Research Council. Dr. Thompson received his Ph.D. from the University of Western Ontario in the Department of Microbiology and Immunology.

Immunovaccine Inc. (TSX VENTURE:IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information